JP2004517045A5 - - Google Patents

Download PDF

Info

Publication number
JP2004517045A5
JP2004517045A5 JP2002521491A JP2002521491A JP2004517045A5 JP 2004517045 A5 JP2004517045 A5 JP 2004517045A5 JP 2002521491 A JP2002521491 A JP 2002521491A JP 2002521491 A JP2002521491 A JP 2002521491A JP 2004517045 A5 JP2004517045 A5 JP 2004517045A5
Authority
JP
Japan
Prior art keywords
alkyl
betulinic acid
cancer
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002521491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/025581 external-priority patent/WO2002016395A1/en
Publication of JP2004517045A publication Critical patent/JP2004517045A/ja
Publication of JP2004517045A5 publication Critical patent/JP2004517045A5/ja
Pending legal-status Critical Current

Links

JP2002521491A 2000-08-18 2001-08-15 癌およびhivの治療用ベツリン酸誘導体のプロドラッグ Pending JP2004517045A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22653600P 2000-08-18 2000-08-18
PCT/US2001/025581 WO2002016395A1 (en) 2000-08-18 2001-08-15 Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv

Publications (2)

Publication Number Publication Date
JP2004517045A JP2004517045A (ja) 2004-06-10
JP2004517045A5 true JP2004517045A5 (https=) 2008-10-02

Family

ID=22849310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002521491A Pending JP2004517045A (ja) 2000-08-18 2001-08-15 癌およびhivの治療用ベツリン酸誘導体のプロドラッグ

Country Status (9)

Country Link
US (3) US6569842B2 (https=)
EP (1) EP1309605A1 (https=)
JP (1) JP2004517045A (https=)
AU (2) AU2001284946B2 (https=)
CA (1) CA2418479C (https=)
NO (1) NO20030748L (https=)
NZ (1) NZ524087A (https=)
WO (1) WO2002016395A1 (https=)
ZA (1) ZA200301269B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943260B2 (en) * 2002-02-02 2005-09-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for obtaining betulinic acid
DE60330407D1 (de) * 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
JP4722031B2 (ja) * 2003-02-11 2011-07-13 ノベリックス・ファーマシューティカルズ・インコーポレイテッド 腫瘍増殖を阻害するための医薬
ES2339450T3 (es) 2003-03-24 2010-05-20 Sterix Limited Derivados de estrogenos como inhibidores de esteroide sulfatasa.
CN101123878A (zh) * 2003-07-29 2008-02-13 信号研发控股有限责任公司 氨基酸前药
WO2005112929A2 (en) * 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
WO2006012725A1 (en) * 2004-08-02 2006-02-09 Ambrilia Biopharma Inc. Lysine based compounds
EA200700611A1 (ru) * 2004-09-10 2008-02-28 Бридж Б. Саксена Производные бетулинола в качестве противораковых агентов
AR051475A1 (es) * 2004-11-05 2007-01-17 Merck & Co Inc Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
JP4810642B2 (ja) * 2004-11-30 2011-11-09 秋田県 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
EP1869063A2 (en) * 2005-03-29 2007-12-26 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
US20070111936A1 (en) 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
BRPI0619936A2 (pt) * 2005-12-16 2011-10-25 Panacos Pharmaceuticals Inc preparação de sais farmacêuticos de ácido 3-o-(3',3'- dimetilsuccinil) betulìnico
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
US20110152229A1 (en) * 2006-11-22 2011-06-23 Duke University Betulinic acid derivatives as anti-hiv agents
US20090062243A1 (en) * 2007-08-03 2009-03-05 Advanced Life Sciences, Inc. Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof
US20110077297A1 (en) * 2008-05-30 2011-03-31 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
US8372808B2 (en) * 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
US20100144688A1 (en) * 2008-12-10 2010-06-10 Advanced Life Sciences, Inc. 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids
RU2551647C2 (ru) * 2012-11-12 2015-05-27 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Трифенилфосфониевые соли лупановых тритерпеноидов, способ получения и применение в качестве противоопухолевых веществ
KR101531821B1 (ko) * 2013-11-27 2015-06-24 주식회사 휴메딕스 페길레이션된 베튤린 유도체를 포함하는 경구 투여용 항암제 조성물
CN107011406A (zh) * 2016-01-28 2017-08-04 思路迪(北京)医药科技有限公司 一种具有抗肿瘤作用的化合物及其制备方法和应用
RU2020113341A (ru) 2017-09-14 2021-10-15 Феникс Байотекнолоджи, Инк. Способ и композиция для лечения вирусной инфекции
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
CA3101643C (en) 2018-06-29 2023-02-21 Dfh Therapeutics Triterpene amine derivatives
WO2020124043A1 (en) * 2018-12-13 2020-06-18 Gordon Erlinda M Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy
JP7153083B2 (ja) 2020-03-31 2022-10-13 フェニックス・バイオテクノロジー・インコーポレイテッド コロナウイルス感染を治療するための方法および組成物
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683531B1 (fr) 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2705097B1 (fr) * 1993-05-11 1995-08-04 Rhone Poulenc Rorer Sa Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5658947A (en) 1995-03-21 1997-08-19 Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma using betalinic acid
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
JPH0987156A (ja) * 1995-09-19 1997-03-31 Pola Chem Ind Inc 光老化防止剤及び皮膚化粧料
US5804575A (en) 1997-03-27 1998-09-08 The Board Of Trustees Of The University Of Illinois Methods of manufacturing betulinic acid
US6048847A (en) * 1997-09-30 2000-04-11 Dabur Research Foundation Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this
US6670345B1 (en) * 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
DE69832363D1 (de) * 1998-03-18 2005-12-22 Dabur Pharma Ltd Betulinsauer Derivate zur Hemmung von Krebswachstum
AU766599B2 (en) 1998-11-18 2003-10-16 Dabur Pharma Ltd. Novel betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors
AU4331700A (en) * 1999-04-07 2000-10-23 Virginia Commonwealth University Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives
WO2002009719A1 (en) 2000-07-31 2002-02-07 The Nisshin Oillio, Ltd. Antitumor agents

Similar Documents

Publication Publication Date Title
JP2004517045A5 (https=)
EP3277276B1 (en) Methods of administering glutaminase inhibitors
JP2022121594A5 (https=)
ES2522971T3 (es) Nuevo derivado de la prostaglandina I2
JP2004514663A5 (https=)
JP2017537126A5 (https=)
JP2003509349A5 (https=)
RU2009102243A (ru) Производные камптотецина с противоопухолевой активностью
JP2021147340A (ja) 化合物、そのナノ粒子及び癌疾患の治療剤
CN110461836B (zh) 一种选择性抑制激酶化合物及其用途
CN115025090A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
JP2004517882A (ja) トリプトライドプロドラッグを使用する抗癌処置
CN102850400A (zh) 喜树碱衍生物及其制备方法、药物组合物与用途
JP2019513812A5 (https=)
FI2968346T3 (fi) Menetelmiä ja koostumuksia gamma-glutamyylisyklin muokkaamiseksi
RU2019100713A (ru) Композиции и способы для лечения рака
JP2007532649A5 (https=)
JP2002510667A5 (https=)
JPWO2021093839A5 (https=)
EP3778612B1 (en) Phosphate derivatives and use thereof
JP2003505513A5 (https=)
JP2013525290A5 (https=)
CN101775032A (zh) 氯硝柳胺磷酸酯、其药学上可接受的盐及其应用
JP2010500971A5 (https=)
RU2010120810A (ru) Гидратированные кристаллические сложные эфиры камптотецина для лечения рака